Insulet Corp. Faces Voluntary Recall of Omnipod 5 Pods Due to Manufacturing Defect
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PODD?
Source: Benzinga
- Product Defect Impact: Insulet Corp. announced a voluntary medical device correction for certain lots of Omnipod 5 Pods due to a manufacturing defect that may cause insulin under-delivery, affecting approximately 1.5% of global annual production and potentially leading to serious medical conditions such as high blood glucose and diabetic ketoacidosis.
- Adverse Event Reports: The company has received 18 reports of serious adverse events related to this defect, highlighting the potential severity of the issue, although Insulet has assured that all other Omnipod products remain safe for use, indicating the company's crisis management capabilities.
- Stock Performance Decline: Insulet shares fell 4.85% to $224.63 in pre-market trading on Friday, nearing a 52-week low, reflecting market concerns about the company's future prospects and indicating a bearish trend in the short term.
- Analyst Ratings and Targets: While Insulet's stock carries a Buy rating with an average price target of $356.64, both Citigroup and Truist Securities have lowered their targets, suggesting a reevaluation of the company's value that may impact investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PODD
Wall Street analysts forecast PODD stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 236.070
Low
316.00
Averages
375.83
High
450.00
Current: 236.070
Low
316.00
Averages
375.83
High
450.00
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insulet Initiates Voluntary Recall of Omnipod 5 Pods Due to Manufacturing Issue
- Stock Decline: Insulet Corporation's shares are down about 3% in Friday trading, currently priced at $227.53, reflecting an $8.54 drop from the previous close of $236.07, indicating market concerns over the company's product issues.
- Product Recall: The company has announced a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through ongoing product monitoring, which could impact user health.
- Potential Risks: Insulet identified that certain Pods from specific lots may have small tears in the internal tubing that delivers insulin, leading to potential insulin leakage instead of full infusion, which could trigger elevated blood glucose levels in users, increasing health risks.
- Historical Trading Range: Over the past year, Insulet's stock has traded between $220.28 and $354.88, and the current decline in stock price may affect investor confidence regarding the company's future performance.
See More
Insulet Stock Drops 4.3% Following Recall of Certain Insulin Devices in the US Due to Leakage Concerns
Insulin Shares Decline: Insulin shares have fallen by 4.3% following recent developments in the market.
Core Recall Impact: The decline is attributed to recalls of certain insulin devices due to safety concerns.
Leakage Risk: The recalls were prompted by risks associated with leakage in some insulin devices.
Market Reaction: Investors are reacting to the potential implications of these recalls on the insulin market.
See More
Insulet Corp. Faces Voluntary Recall of Omnipod 5 Pods Due to Manufacturing Defect
- Product Defect Impact: Insulet Corp. announced a voluntary medical device correction for certain lots of Omnipod 5 Pods due to a manufacturing defect that may cause insulin under-delivery, affecting approximately 1.5% of global annual production and potentially leading to serious medical conditions such as high blood glucose and diabetic ketoacidosis.
- Adverse Event Reports: The company has received 18 reports of serious adverse events related to this defect, highlighting the potential severity of the issue, although Insulet has assured that all other Omnipod products remain safe for use, indicating the company's crisis management capabilities.
- Stock Performance Decline: Insulet shares fell 4.85% to $224.63 in pre-market trading on Friday, nearing a 52-week low, reflecting market concerns about the company's future prospects and indicating a bearish trend in the short term.
- Analyst Ratings and Targets: While Insulet's stock carries a Buy rating with an average price target of $356.64, both Citigroup and Truist Securities have lowered their targets, suggesting a reevaluation of the company's value that may impact investor confidence.
See More
Insulet Initiates Voluntary Recall of Omnipod 5 Insulin Delivery Pods
- Product Recall: Insulet Corporation has voluntarily recalled certain lots of its Omnipod 5 insulin delivery pods in the U.S. due to a manufacturing defect causing insulin leakage, affecting approximately 1.5% of its annual production, which could jeopardize patient blood glucose control.
- Safety Concerns: The defect arises from a small tear in the internal tubing of some devices, potentially leading to insufficient insulin delivery; Insulet has received 18 reports of serious adverse events linked to this issue, with no fatalities reported.
- FDA Notification: Insulet has notified the FDA about the recall, demonstrating the company's commitment to product safety and taking proactive measures to protect patient health by ensuring timely replacements for affected products.
- Customer Guidance: The company advises customers using affected lots to seek free replacements immediately, reflecting Insulet's dedication to customer safety, although this situation may negatively impact future sales and brand reputation.
See More
Adobe CEO Resignation Triggers Stock Volatility
- Adobe CEO Change: Adobe's CEO Shantanu Narayen announced his resignation after a successor is named, causing an 8% drop in stock price despite first-quarter earnings beating expectations, indicating market sensitivity to leadership changes.
- Fertilizer Stocks Rise: Fertilizer companies saw stock increases due to escalating tensions in the Strait of Hormuz, with Intrepid Potash and Nutrien both climbing 2% and Mosaic up 1%, reflecting market concerns over supply chain disruptions and their potential impact on the agriculture sector.
- Ulta Beauty Earnings Miss: Ulta Beauty reported fourth-quarter earnings of $8.01 per share, falling short of the $8.03 expected by analysts, leading to a 7.4% drop in stock price, despite revenue of $3.90 billion exceeding forecasts, highlighting market focus on profitability.
- Insulet Recall: Insulet is recalling certain batches of its Omnipod 5 devices due to small tears in internal tubing, resulting in some users being hospitalized but no deaths reported, causing a 4% drop in stock price and emphasizing the impact of safety issues on company reputation.
See More
Movers: Adobe, Micron, Western Digital, Coinbase, Ulta Beauty, CF Industries, and Others
- Stock Market Performance: Stocks experienced an upward trend on Friday, indicating positive market sentiment.
- Oil Prices: A decline in oil prices contributed to the favorable trading conditions.
- Inflation Data: The latest personal consumption expenditures price index revealed that inflation was slightly higher than expected in February.
- Economic Indicators: The combination of lower oil prices and inflation data influenced investor behavior in the stock market.
See More
Insulet Initiates Voluntary Recall of Omnipod 5 Pods Due to Manufacturing Issue
- Stock Decline: Insulet Corporation's shares are down about 3% in Friday trading, currently priced at $227.53, reflecting an $8.54 drop from the previous close of $236.07, indicating market concerns over the company's product issues.
- Product Recall: The company has announced a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through ongoing product monitoring, which could impact user health.
- Potential Risks: Insulet identified that certain Pods from specific lots may have small tears in the internal tubing that delivers insulin, leading to potential insulin leakage instead of full infusion, which could trigger elevated blood glucose levels in users, increasing health risks.
- Historical Trading Range: Over the past year, Insulet's stock has traded between $220.28 and $354.88, and the current decline in stock price may affect investor confidence regarding the company's future performance.
See More
Insulet Stock Drops 4.3% Following Recall of Certain Insulin Devices in the US Due to Leakage Concerns
Insulin Shares Decline: Insulin shares have fallen by 4.3% following recent developments in the market.
Core Recall Impact: The decline is attributed to recalls of certain insulin devices due to safety concerns.
Leakage Risk: The recalls were prompted by risks associated with leakage in some insulin devices.
Market Reaction: Investors are reacting to the potential implications of these recalls on the insulin market.
See More
Insulet Corp. Faces Voluntary Recall of Omnipod 5 Pods Due to Manufacturing Defect
- Product Defect Impact: Insulet Corp. announced a voluntary medical device correction for certain lots of Omnipod 5 Pods due to a manufacturing defect that may cause insulin under-delivery, affecting approximately 1.5% of global annual production and potentially leading to serious medical conditions such as high blood glucose and diabetic ketoacidosis.
- Adverse Event Reports: The company has received 18 reports of serious adverse events related to this defect, highlighting the potential severity of the issue, although Insulet has assured that all other Omnipod products remain safe for use, indicating the company's crisis management capabilities.
- Stock Performance Decline: Insulet shares fell 4.85% to $224.63 in pre-market trading on Friday, nearing a 52-week low, reflecting market concerns about the company's future prospects and indicating a bearish trend in the short term.
- Analyst Ratings and Targets: While Insulet's stock carries a Buy rating with an average price target of $356.64, both Citigroup and Truist Securities have lowered their targets, suggesting a reevaluation of the company's value that may impact investor confidence.
See More
Insulet Initiates Voluntary Recall of Omnipod 5 Insulin Delivery Pods
- Product Recall: Insulet Corporation has voluntarily recalled certain lots of its Omnipod 5 insulin delivery pods in the U.S. due to a manufacturing defect causing insulin leakage, affecting approximately 1.5% of its annual production, which could jeopardize patient blood glucose control.
- Safety Concerns: The defect arises from a small tear in the internal tubing of some devices, potentially leading to insufficient insulin delivery; Insulet has received 18 reports of serious adverse events linked to this issue, with no fatalities reported.
- FDA Notification: Insulet has notified the FDA about the recall, demonstrating the company's commitment to product safety and taking proactive measures to protect patient health by ensuring timely replacements for affected products.
- Customer Guidance: The company advises customers using affected lots to seek free replacements immediately, reflecting Insulet's dedication to customer safety, although this situation may negatively impact future sales and brand reputation.
See More
Adobe CEO Resignation Triggers Stock Volatility
- Adobe CEO Change: Adobe's CEO Shantanu Narayen announced his resignation after a successor is named, causing an 8% drop in stock price despite first-quarter earnings beating expectations, indicating market sensitivity to leadership changes.
- Fertilizer Stocks Rise: Fertilizer companies saw stock increases due to escalating tensions in the Strait of Hormuz, with Intrepid Potash and Nutrien both climbing 2% and Mosaic up 1%, reflecting market concerns over supply chain disruptions and their potential impact on the agriculture sector.
- Ulta Beauty Earnings Miss: Ulta Beauty reported fourth-quarter earnings of $8.01 per share, falling short of the $8.03 expected by analysts, leading to a 7.4% drop in stock price, despite revenue of $3.90 billion exceeding forecasts, highlighting market focus on profitability.
- Insulet Recall: Insulet is recalling certain batches of its Omnipod 5 devices due to small tears in internal tubing, resulting in some users being hospitalized but no deaths reported, causing a 4% drop in stock price and emphasizing the impact of safety issues on company reputation.
See More
Movers: Adobe, Micron, Western Digital, Coinbase, Ulta Beauty, CF Industries, and Others
- Stock Market Performance: Stocks experienced an upward trend on Friday, indicating positive market sentiment.
- Oil Prices: A decline in oil prices contributed to the favorable trading conditions.
- Inflation Data: The latest personal consumption expenditures price index revealed that inflation was slightly higher than expected in February.
- Economic Indicators: The combination of lower oil prices and inflation data influenced investor behavior in the stock market.
See More
